GenePOC Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GenePOC Inc. - overview
Established
2007
Location
Quebec City, -, Canada
Primary Industry
Medical Devices & Equipment
About
GenePOC Inc. specializes in developing innovative molecular diagnostics solutions to help healthcare professionals quickly and accurately identify infectious diseases, enhancing patient care and treatment outcomes. Founded in 2007, GenePOC Inc. is based in Quebec City, Canada, and focuses on molecular diagnostics for infectious diseases.
The company underwent a significant change in 2019 when Meridian Bioscience agreed to acquire GenePOC's Molecular Diagnostic Platform for up to USD 120 million, marking a pivotal point in its business strategy. The acquisition is set to enhance the development and distribution of its diagnostic tools. GenePOC has completed three deals to date, with the most recent deal occurring on April 30, 2019. The total amount raised by the company is USD 50.
00 mn, primarily from the TRADE SALE in 2019, which involved Meridian Bioscience, Inc. GenePOC Inc. specializes in molecular diagnostics, providing solutions that enable rapid detection of infectious diseases. The company’s products enhance the capabilities of healthcare providers by offering accurate testing that responds to various medical needs.
By focusing on improving diagnostic speed and accuracy, GenePOC aims to support healthcare facilities in managing patient treatment effectively. GenePOC generates revenue through its diagnostic products and services, which are offered under a structured model designed to meet the needs of healthcare providers. Revenue is primarily derived from direct sales of diagnostic kits and associated services, tailored to the demands of healthcare institutions. GenePOC plans to leverage the recent acquisition by Meridian Bioscience to enhance its product line and expand its market reach.
The funding from Meridian Bioscience will be utilized to accelerate the development of new innovative diagnostic tools aimed at improving patient outcomes. The strategy includes focusing on launching new products that will cater to evolving healthcare demands. Additionally, GenePOC intends to expand its presence in North America and Europe, specifically targeting markets in the United States and Canada, with a goal to enhance its market share by 2022.
Current Investors
Debiopharm Group, Emerillon Capital
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.genepoc-diagnostics.com
Verticals
Big Data
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.